5-HT3-Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer Treatment

  title={5-HT3-Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer Treatment},
  author={M. Aapro},
  pages={109 - 97}
  • M. Aapro
  • Published 2005
  • Medicine
  • Oncology
  • The 5-HT3-receptor antagonists, considered as ‘gold standard’ therapy for cancer patients, are generally perceived to have similar efficacy and safety profiles, andmost antiemetic guidelines do not distinguish between agents. However, important pharmacological differences exist between agents, which may translate into potential benefits for some patients. In particular, 5-HT3-receptor antagonists vary in the nature of their receptor antagonism and plasma half-lives, possibly leading to… CONTINUE READING
    37 Citations

    Figures, Tables, and Topics from this paper

    Explore Further: Topics Discussed in This Paper

    Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia
    • 16
    • PDF
    Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
    • T. Machu
    • Chemistry, Medicine
    • Pharmacology & therapeutics
    • 2011
    • 59
    Ondansetron: a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting
    • 19


    Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
    • N. Minton
    • Medicine
    • British journal of clinical pharmacology
    • 1994
    • 20
    Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
    • C. Lindley, P. Blower
    • Medicine
    • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
    • 2000
    • 34
    • PDF
    Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients.
    • O. Koriech
    • Medicine
    • Clinical oncology (Royal College of Radiologists (Great Britain))
    • 1995
    • 29
    Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
    • 235